Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

While ketogenic diets (KDs) may have potential as adjunct treatments for gastrointestinal diseases, there is little knowledge on how the fat source of these diets impacts intestinal health. The objective of this study was to investigate how the source of dietary fat of KD influences experimental colitis. We fed nine-week-old male C57BL/6J mice (n = 36) with a low-fat control diet or KD high either in saturated fatty acids (SFA-KD) or polyunsaturated linoleic acid (LA-KD) for four weeks and then induced colitis with dextran sodium sulfate (DSS). To compare the diets, we analyzed macroscopic and histological changes in the colon, intestinal permeability to fluorescein isothiocyanate−dextran (FITC–dextran), and the colonic expression of tight junction proteins and inflammatory markers. While the effects were more pronounced with LA-KD, both KDs markedly alleviated DSS-induced histological lesions. LA-KD prevented inflammation-related weight loss and the shortening of the colon, as well as preserved Il1b and Tnf expression at a healthy level. Despite no significant between-group differences in permeability to FITC–dextran, LA-KD mitigated changes in tight junction protein expression. Thus, KDs may have preventive potential against intestinal inflammation, with the level of the effect being dependent on the dietary fat source.

Details

Title
Ketogenic Diet Protects from Experimental Colitis in a Mouse Model Regardless of Dietary Fat Source
Author
Luiskari, Lotta 1   VIAFID ORCID Logo  ; Lindén, Jere 2   VIAFID ORCID Logo  ; Lehto, Markku 3   VIAFID ORCID Logo  ; Salmenkari, Hanne 3   VIAFID ORCID Logo  ; Korpela, Riitta 1 

 Department of Pharmacology, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland 
 Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, 00014 Helsinki, Finland; [email protected]; Finnish Centre for Laboratory Animal Pathology, Helsinki Institute of Life Science, University of Helsinki, 00014 Helsinki, Finland 
 Folkhälsan Institute of Genetics, Folkhälsan Research Center, 00290 Helsinki, Finland; [email protected] (M.L.); [email protected] (H.S.); Department of Nephrology, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland 
First page
1348
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
20726643
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3053152638
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.